Company news

TriSalus Life Sciences, Inc. news in 2026

TriSalus Life Sciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum

October 29, 2026

TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call

October 20, 2026

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization

September 22, 2026

TriSalus Life Sciences Reports Second Quarter 2026 Results

August 6, 2026

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

July 28, 2026

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call

July 16, 2026

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

June 10, 2026

TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

May 12, 2026

TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

May 4, 2026

TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call

April 28, 2026

TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

April 9, 2026

TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer

April 6, 2026

TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models

March 17, 2026

TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance

March 4, 2026

TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call

February 24, 2026

TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering

February 20, 2026

TriSalus Life Sciences Proposes Public Offering

February 19, 2026

TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

February 9, 2026

TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

January 12, 2026

Calls in 2026

Decks in 2026